Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
June 27 2023 - 7:30AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) diseases, and Partex N.V. Group (“Partex”), the first
Data-to-Drugs digital pharma platform, today announced a strategic
partnership with the overall ambition to reshape the future of the
biopharma business model.
By combining Anavex's innovative small molecule
precision medicine drug development platform and Partex's
disruptive approach of Artificial Intelligence (AI) enabled drug
development and healthcare sales marketing, this collaboration is
intended to drive efficiency, effectiveness, and innovation across
the value chain with patient-centric focus at every step.
Under the partnership, Anavex and Partex intend
to co-develop a disease-focused Patient App ecosystem. The first
feature will be to inform patients and caregivers on preventive and
curative options available in clinics and on the market. Further,
Partex will implement AI-based ‘Healthcare Sales Marketing’ in
preparation for Anavex’s late stage drug pipeline.
Gunjan Bhardwaj, PhD, CEO of Partex, commented:
“We are excited to embark on this impactful journey together with
Anavex. We will start by extending our patient ecosystem together.
Further, we intend to leverage our Life Sciences Language
Processing platform with Generative Artificial Intelligence
capabilities, which is expected to significantly improve patient
outcomes.”
"As a biopharmaceutical Company with a
proprietary late stage pipeline for CNS indications, Anavex brings
expertise in precision medicine drug development to the partnership
and we are excited to collaborate with Partex and fully leverage AI
to expand beyond our R&D into healthcare sales marketing to
bring better treatment options to patients in a patient centric
way,” said, Christopher U Missling, PhD, President and Chief
Executive Officer of Anavex.
About Partex N.V. Group
Partex N.V. is the first digital pharma platform
that is set to be the largest AI-powered Drug Assets Manager. Its
unique approach is enabled by a decentralized RWD (real-world data)
exchange and an AI-powered & validated decision-making
capability. Partex covers all key steps in the drug discovery and
drug development value chain.Within the Partex ecosystem, patients
keep ownership of their data and they are rewarded for
participating in research projects. Partex’s proprietary AI/ML
(Artificial Intelligence/ Machine Learning) algorithms enable key
industry players to develop life-saving drugs while also developing
own drug assets.With a global presence that extends from
Asia-Pacific to the Americas, with offices currently in India,
Germany, Switzerland and USA, Partex’s vision is to transform the
Life Science Industry by curing incurable diseases and increasing
humanity's longevity.Partex group companies:www.innoplexus.com,
www.cureteq.com , www.perpetualblock.io , www.amrit.ai,
www.assay.works. For more information, visit www.partex.io.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of novel therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders, including
Alzheimer's disease, Parkinson's disease, Rett syndrome, and other
central nervous system (CNS) diseases, pain, and various types of
cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine),
has successfully completed a Phase 2a and recently a Phase 2b/3
clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept
study in Parkinson's disease dementia, and both a Phase 2 and a
Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is
an orally available drug candidate that restores cellular
homeostasis by targeting sigma-1 and muscarinic receptors.
Preclinical studies demonstrated its potential to halt and/or
reverse the course of Alzheimer's disease. ANAVEX®2-73 also
exhibited anticonvulsant, anti-amnesic, neuroprotective, and
anti-depressant properties in animal models, indicating its
potential to treat additional CNS disorders, including epilepsy.
The Michael J. Fox Foundation for Parkinson's Research previously
awarded Anavex a research grant, which fully funded a preclinical
study to develop ANAVEX®2-73 for the treatment of Parkinson's
disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic
receptors, is a promising clinical stage drug candidate
demonstrating disease-modifying activity against the major
hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid, and tau pathologies. In
preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:Anavex
Life Sciences Corp.Research & Business DevelopmentToll-free:
1-844-689-3939Email: info@anavex.com
Investors:Andrew J.
BarwickiInvestor RelationsTel: 516-662-9461Email:
andrew@barwicki.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2024 to May 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2023 to May 2024